Expand AIM Menu
AIM MENU

AIM Latest Press Releases

-- December 1, 2025 --

AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series Globe Newswire 8:55 AM

-- November 18, 2025 --

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program Globe Newswire 8:55 AM

-- November 10, 2025 --

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer Globe Newswire 8:55 AM

-- November 4, 2025 --

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting Globe Newswire 9:05 AM

-- November 3, 2025 --

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue Globe Newswire 8:55 AM

-- October 20, 2025 --

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit Globe Newswire 9:15 AM

-- September 25, 2025 --

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors Globe Newswire 8:45 AM

-- September 22, 2025 --

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth Globe Newswire 9:00 AM

-- September 4, 2025 --

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland Globe Newswire 11:00 AM

-- August 21, 2025 --

AIM ImmunoTech Announces Release of the Next CEO Corner Segment Globe Newswire 9:00 AM

-- August 15, 2025 --

JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025 ACCESS Newswire 10:00 AM

-- August 14, 2025 --

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech Globe Newswire 8:55 AM

-- August 6, 2025 --

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) Globe Newswire 9:00 AM

-- August 4, 2025 --

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval Globe Newswire 9:00 AM

-- July 31, 2025 --

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering Globe Newswire 9:00 AM

-- July 29, 2025 --

AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering Globe Newswire 9:00 AM

-- July 28, 2025 --

AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer Globe Newswire 9:00 AM

-- July 18, 2025 --

JTC Team Announces Participating Line Up for the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference ACCESS Newswire 11:00 AM
Market Data Delayed 15 Minutes